H.C. Wainwright analyst Robert Burns raised the firm’s price target on Revolution Medicines to $32 from $30 and keeps a Buy rating on the shares.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RVMD:
- Revolution to regain rights to RMC-4630 following Sanofi deal termination
- Sanofi terminates SHP2 Inhibitor development pact with Revolution Medicines
- Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofi’s Termination of SHP2 Inhibitor Development and Commercialization Collaboration
- Revolution Medicines to Participate in Upcoming Investor Conferences
- Revolution Medicines reports Q3 EPS (87c), consensus (84c)